Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Fase 1-undersøgelse af ACE-232 til behandling af patienter med metastatisk kastrationsresistent prostatacancer

24. september 2026 opdateret af: Acerand Therapeutics (Hong Kong) Limited

En fase 1-undersøgelse til vurdering af sikkerhed, farmakokinetik, farmakodynamik og foreløbig effektivitet af ACE-232 hos patienter med metastatisk kastrationsresistent prostatacancer (CRPC)

This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The study consists of two parts, Phase 1A dose escalation and Phase 1B dose optimization. Phase 1A aims to assess the safety, tolerability, pharmacokinetic (PK) profile, and changes in pharmacodynamic (PD) markers in patients treated with ACE-232, and to determine the maximum tolerated dose (MTD), if applicable. In Phase 1B, patients with AR gene alterations will be treated at two different dose levels to establish the recommended Phase 2 dose (RP2D).

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

88

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

  • Forenede Stater
    • California
      • La Jolla, California, Forenede Stater, 92093
        • Rekruttering
        • University of California San Diego, Moores Cancer Center
    • Florida
      • Tampa, Florida, Forenede Stater, 33612
        • Rekruttering
        • Moffitt Cancer Center, Tampa
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21201
        • Rekruttering
        • University of Maryland, Greenebaum Comprehensive Cancer Center
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Rekruttering
        • Harvard Medical School-Massachusetts General Hospital
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55455
        • Rekruttering
        • M Health Fairview Clinics and Surgery Center
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68130
        • Trukket tilbage
        • Xcancer (Urology Cancer Center)
    • South Carolina
      • Myrtle Beach, South Carolina, Forenede Stater, 29572
        • Rekruttering
        • Carolina Urologic Research Center
    • Washington
      • Seattle, Washington, Forenede Stater, 98109
        • Rekruttering
        • Fred Hutchinson Cancer Research Center
  • Kina
    • China
      • Beijing, China, Kina, 102200
      • Hangzhou, China, Kina, 310022
        • Ikke rekrutterer endnu
        • Zhejiang Cancer Hospital
        • Kontakt:
      • Shanghai, China, Kina, 200127
        • Ikke rekrutterer endnu
        • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
        • Kontakt:
      • Zhengzhou, China, Kina, 450008
        • Ikke rekrutterer endnu
        • Henan Cancer Hospital
        • Kontakt:
    • Fujian
      • Fuzhou, Fujian, Kina
        • Rekruttering
        • Fujian Cancer Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Han

Beskrivelse

Inclusion Criteria:

  • Provide written informed consent
  • Metastatic Castration-resistant Prostate Cancer with ongoing androgen - deprivation therapy (ADT) or have bilateral orchiectomy
  • Difficult to treat or intolerant to standard treatment (post at least 1 line of NHA and taxane-based chemo in mHSPC or mCRPC), suitable for investigational treatment;
  • Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Has a life expectancy of at least 6 months
  • Adequate organ function and bone marrow function

Exclusion Criteria:

  • Receiving any anti-cancer drugs or other treatment, major surgery, extensive radiation therapy, or local radiation therapy within protocol-defined wash-out period;
  • Concomitant use of medications or herbal supplements known to be moderate to strong CYP3A4 inhibitors/inducers, or P-gp inhibitors, known to prolong the QT interval.
  • Any previous treatment-related toxicities have not recovered.
  • Spinal cord compression or known brain metastases or leptomeningeal carcinomatosis.
  • Severe cardiovascular disorders.
  • Known gastrointestinal (GI) disorder or GI procedure
  • History of gastric and duodenal perforation.
  • History of pituitary dysfunction.
  • Poorly controlled diabetes mellitus.
  • Active or uncontrolled autoimmune disease
  • Active infections, or a known history of HIV infection, or a known active hepatitis B or C, or a known active tuberculosis.
  • Other malignancies requiring treatment within 3 years prior to the first dose of study drug
  • Known allergy or hypersensitivity to any of the excipients of ACE-232.
  • Has other medical conditions that at the discretion of the investigator interfere with safety or efficacy evaluation, or treatment compliance.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: ACE-232

Administered once daily (QD) continuously at the assigned dose level in accordance with the standard 3+3 dose-escalation scheme
Medicin: ACE-232 tablets

ACE-232 tablets will be administered orally daily as a continuous regimen together with Dexamethasone and Fludrocortisone. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of patients experiencing adverse events (AEs)/serious adverse events (SAEs)
Tidsramme: From time of information consent to 30 days post last dose, up to approximately 37 months

Number of patients with incidence of adverse events and with serious adverse events including changes from baseline in laboratory parameters, vital signs, ECGs, and physical examination, etc.
From time of information consent to 30 days post last dose, up to approximately 37 months
Number of patients experiencing dose limiting toxicity (DLT), as defined in the protocol
Tidsramme: From the first dose of ACE-232 on Cycle 1 Day 1 up to and including the planned end of Cycle 1 (at the end of 28 days)

A DLT is defined as any toxicity events related to ACE-232 that occur from the first dose of study treatment until the planned end date of Cycle 1 (DLT assessment period), meeting the criteria specified in protocol.
From the first dose of ACE-232 on Cycle 1 Day 1 up to and including the planned end of Cycle 1 (at the end of 28 days)
Recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD)
Tidsramme: Up to approximately 37 months

RP2D will be finally determined by the SMC and sponsor based on all data from the dose escalation module and backfill module, as well as the exposure-response relationship evaluated (if available). MTD is defined as the maximum dose level at which ≤1 patient have DLTs during the DLT observation period, and it should be determined with 6 evaluable patients.
Up to approximately 37 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Pharmacokinetics characterization by using Area under the plasma concentration versus time curve (AUC)
Tidsramme: Up to approximately 37 months

To determine the pharmacokinetics (PK) using AUC of ACE-232 after a single dose and at steady state after multiple doses.
Up to approximately 37 months
Pharmacokinetics characterization by using Maximum concentration (Cmax)
Tidsramme: Up to approximately 37 months

To determine the pharmacokinetics (PK) using Cmax of ACE-232 after a single dose and at steady state after multiple doses
Up to approximately 37 months
Prostate Specific Antigen (PSA) response
Tidsramme: Up to approximately 37 months

PSA response is defined as PSA decline of 30% and 50% from baseline at any time point
Up to approximately 37 months
Objective Response Rate (ORR)
Tidsramme: Up to approximately 37 months

ORR is defined as a complete response (CR) or partial response (PR), as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) and Prostate Cancer Working Group Criteria 3 (PCWG3 criteria), in patients with measurable disease at baseline.
Up to approximately 37 months
Duration of Response (DoR)
Tidsramme: Up to approximately 37 months

DOR is defined, for patients with an objective response, as the time from first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or death due to any cause.
Up to approximately 37 months
Radiographic Progression Free Survival (rPFS)
Tidsramme: Up to approximately 37 months

rPFS is defined as the time from the first dose of ACE-232 to the first documented disease progression by either RECIST progression and/or progression on bone scan by PCWG3 or death due to any cause, whichever occurs first.
Up to approximately 37 months
Overall Survival (OS)
Tidsramme: Up to approximately 37 months

OS is defined as the time from the first dose of ACE-232 to the date of death due to any cause.
Up to approximately 37 months
Blood concentration of steroid hormone
Tidsramme: Up to approximately 37 months

To determine the blood concentration of steroid hormones at various timepoints and change from baseline
Up to approximately 37 months

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Gene aberrations
Tidsramme: Up to approximately 37 months

To determine the gene aberrations in circulating tumor DNA (ctDNA), and its association with tumor response or resistance to ACE-232
Up to approximately 37 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Acerand Therapeutics (Hong Kong) Limited

Efterforskere

  • Studieleder: Derek Yang, MD, Acerand Therapeutics

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

12. maj 2025

Primær færdiggørelse (Anslået)

31. december 2028

Studieafslutning (Anslået)

31. december 2028

Datoer for studieregistrering

Først indsendt

19. januar 2025

Først indsendt, der opfyldte QC-kriterier

24. januar 2025

Først opslået (Faktiske)

30. januar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

24. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • ACE-232-001

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

No IPD sharing plan at this moment, which might be changed during the study process or when the results come out.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner